Generic antifungal drug shows promise in early comparison study
NCT ID NCT06983665
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared a new generic version of liposomal amphotericin B (an antifungal drug) to the brand-name version (AmBisome®) in 58 healthy Chinese adults. Each volunteer received a single dose of both drugs at different times to see if the generic works the same way in the body. The goal was to check bioequivalence, meaning the generic should release the same amount of drug into the bloodstream. Safety was also monitored. This is a key step toward offering a more affordable treatment option for serious fungal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Liposomal amphotericin B
- What this could lead to
- If successful, this could lead to a more affordable generic version of an important antifungal drug.
- What could go wrong
- This is a small, early-stage bioequivalence study in healthy people, not patients. It does not test effectiveness against infections, so the generic may still fail in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinan Central Hospital, No.105, Jiefang Road,
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Blood test clues could make antifungal dosing safer for transplant patients
- Leukemia Patients' hidden threat: fungal infections under microscope
- Tiny study aims to Fine-Tune fungal drug dosing during plasma exchange
- Scientists probe hidden causes of deadly parasite relapse in HIV patients